Related Experiment Video

Updated: May 8, 2026

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

Direct cardiovascular effects of glucagon like peptide-1

Asfandyar Sheikh1

  • 1Dow Medical College, Dow University of Health Sciences, Baba-e-Urdu Road, Karachi, Pakistan. asfandyarsheikh@gmail.com.

Diabetology & Metabolic Syndrome
|August 31, 2013
PubMed

Insights

Glucagon-like peptide-1 (GLP-1) therapies show promise for type 2 diabetes (T2DM) by offering cardiovascular benefits beyond traditional treatments. This review focuses on the direct cardiovascular effects of GLP-1 and its analogs.

Area of Science:

  • Endocrinology
  • Cardiology
  • Pharmacology

Background:

  • Type 2 diabetes mellitus (T2DM) treatments primarily address insulin resistance and beta-cell dysfunction.
  • Conventional anti-diabetic drugs often fail to significantly reduce macrovascular complications.
  • Emerging therapies, including glucagon-like peptide-1 (GLP-1) based treatments, present novel cardiovascular implications.

Purpose of the Study:

  • To review the direct cardiovascular effects of glucagon-like peptide-1 (GLP-1) and its analogs.
  • To explore the potential of GLP-1 based therapies in mitigating cardiovascular morbidity and mortality in T2DM patients.

Main Methods:

  • Literature review of studies investigating GLP-1 and its analogs.
  • Analysis of direct cardiovascular mechanisms of action.
  • Synthesis of current evidence on cardiovascular outcomes.

Main Results:

  • GLP-1 and its analogs exert direct cardiovascular effects.
  • These effects may contribute to reduced cardiovascular events in T2DM.
  • Specific mechanisms include improved cardiac function and vascular health.

Conclusions:

  • GLP-1 based therapies offer a promising therapeutic avenue for T2DM with significant cardiovascular benefits.
  • Further research into the direct cardiovascular actions of GLP-1 is warranted.
  • These agents represent a potential shift in managing T2DM, focusing on both glycemic control and cardiovascular protection.

More Related Videos

Combined Intravital Microscopy and Contrast-enhanced Ultrasonography of the Mouse Hindlimb to Study Insulin-induced Vasodilation and Muscle Perfusion08:22

Combined Intravital Microscopy and Contrast-enhanced Ultrasonography of the Mouse Hindlimb to Study Insulin-induced Vasodilation and Muscle Perfusion

Published on: March 20, 2017

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...